Introduction
============

Gastric cancer (GC) is one of most common malignancies and ranks the third leading cause of cancer-related mortality worldwide [@B1]. The cascade of GC progress develops through chronic gastritis, atrophy, intestinal metaplasia (IM) and intraepithelial neoplasia (IN) before eventually evolving to GC [@B2]. Gastric IM and IN are precancerous lesions that trigger at least 10-fold increase in the risk of developing GC [@B3], [@B4]. Despite great improvements made in the prognosis of early gastric cancer (EGC), the survival outcomes of most GC patients were unsatisfactory since they were diagnosed at an advanced stage with a relatively poor survival outcome [@B5], [@B6]. Therefore, earlier detection of GC and precancerous lesions would promote preferable management of the disease. Currently, gastroscopy with biopsy sampling is still the most effective approach for confirming GC. However, it is an invasive procedure and causes discomfort to many subjects. Frequently, patients are reluctant to undergo gastroscopy, which leads to delayed treatment. Conventional serological tumor biomarkers, such as carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), may help but lack specificity and are not sensitive for identifying GC in its early stage or with precancerous lesions. Thus, new diagnostic methods with high sensitivity to detect early-stage malignancies in a non-invasive and cost-effective manner are definitely in need.

Both genetic and epigenetic alterations contribute to gastric carcinogenesis. The transcriptional silencing of tumor-suppressor genes (TSGs) through aberrant DNA methylation is thought to be a key epigenetic event in the origin of various cancers [@B7], [@B8]. Accumulating data strongly suggested that methylated DNA in body fluids is detectable ahead of cancer diagnosis [@B9], [@B10]. Techniques based on cell free DNA (cfDNA) circulating in body fluid of patients represent a promising alternative for GC screening. Our previous studies have discovered a panel of TSGs, including zinc finger of the cerebellum 1 (*ZIC1*), *Klotho*, Homeobox D10 (*HOXD10*) genes that were silenced epigenetically in GC as well as precancerous lesions [@B11]-[@B13]. Meanwhile, we detected aberrant DNA methylation of *ZIC1* in the blood samples from patients with GC and IN, indicating its potential role for early detection of GC and precancerous lesions in a non-invasive way [@B14]. However, the sensitivity of a single gene methylation is still unsatisfying, combined detection of several genes might be a decent solution.

To our knowledge, few studies investigated aberrant DNA methylation in blood samples from GCs, in parallel with samples from patients with precancerous lesions and from healthy individuals. In this paper, we embark upon identifying potential biomarkers for the early diagnosis of GC and precancerous lesions. We firstly conducted a selection study and chose *ZIC1*, *HOXD10* and runt-related transcription factor 3 (*RUNX3*) for further validation, then we examined the methylation status of the three genes in plasma from patients with advanced gastric cancer (AGC), EGC, IN, IM and normal controls (NCs). The correlation between promoter hypermethylation of these genes and clinical data was analyzed. Besides, the association of genes methylation status with histopathologic characteristics in GCs was also estimated. Finally, we categorized the subjects with GC and IN in a gastric cancer and intraepithelial neoplasia (GnI) group and compared the diagnostic and predictive ability of single detection or combination of plasma *ZIC1*, *HOXD10* and *RUNX3* promoter hypermethylation in both GC and GnI groups.

Materials and methods
=====================

Patients and blood samples
--------------------------

Blood samples were collected from GC, IN and IM patients diagnosed at Sir Run Run Shaw Hospital from June 2013 to December 2015. All subjects underwent gastroendoscopy and the exclusion criteria were shown as follows: patients who had gastrointestinal disorders with other causes; those with other organic diseases or gastric metastases from other malignancies; patients who had already received surgical treatment or preoperative chemotherapy or radiation therapy. We also recruited samples from healthy volunteers as NCs. Blood was prepared with Ethylenediaminetetraacetic acid (EDTA) and plasma was separated immediately by centrifuging blood at 2500 × *rpm*for 15 minutes. Then, samples were grouped based on the histopathological diagnosis. When multiple pathological changes occur in one case, the diagnosis is subject to the lesion with higher grade. The tumor stage of GCs was classified according to the American Joint Committee on Cancer (AJCC) staging manual [@B15].

All participants provided written informed consent before enrolment. The study protocol was approved by the Clinical Research Ethics Committee of the Institute of Gastroenterology of Zhejiang University.

DNA Isolation and bisulfite modification
----------------------------------------

DNA was extracted from plasma sample (400 μL) according to the instruction of the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The extracted DNA was dissolved in 50 μL of elution buffer and stored at -20°C. Bisulfite conversion was subsequently performed using the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA). The modified DNA was resuspended in 10 μL of elution buffer and stored at -20°C until use.

Methylation-specific polymerase chain reaction (MSP)
----------------------------------------------------

The promoter hypermethylation of *ZIC1*, *HOXD10* and*RUNX3* was detected by MSP assays utilizing the above-mentioned bisulfite-modified DNA as templates. DNA from BGC-823 (gastric cancer cell line) was used as a positive control and nuclease-free water was used as a negative control. The methylation-specific primer sequences and corresponding annealing temperatures are listed in **Table [S1](#SM1){ref-type="supplementary-material"}**. The PCR protocol was provided previously [@B14].

Evaluation of serum CEA, CA19-9 and H. pylori status
----------------------------------------------------

Serum CEA and CA19-9 levels were evaluated by Enzyme-linked immunosorbent assay. CEA and CA19-9 were considered positive as ≥5 ng/mL and ≥40 U/mL, respectively. H. pylori infection was diagnosed when there were positive results for both RUT and 13C-urea breath test (UBT) or histological analysis.

Statistical Analyses
--------------------

All statistical analyses were performed by SPSS 20.0 software (IBM, SPSS, Chicago, IL, USA). Continuous variables were shown as mean±SD and compared by Student\'s t test, while categorical data were checked by Chi-square test or Fisher\'s exact test where appropriate. The correlation between the clinical features and DNA hypermethylation was calculated by the Chi-square test. The sensitivity and specificity with 95% confidence intervals (CIs) of DNA methylation assays of specific genes were analyzed. For predicting the risk of GC or precancerous lesions, we used odds ratios (ORs) with 95%CIs as a measure of association. Youden index was calculated to assess the accuracy of plasma DNA assays. All *P* values were two-sided and *P*\<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

20 samples from 10 GCs and 10 NCs were used for the selection study. Then, a total of 251 cases were enrolled in the validation study, including 131 GCs (91 AGC and 40 EGC), 56 IN patients, 30 IM patients and 34 NCs. The mean age of the GC, IN, IM and NC group was 61.1, 59.6, 57.8 and 56.5 (years), respectively. The gender ratio (male: female) was 88:43 in GC, 37:19 in IN, 3:2 in IM and 11:6 in NC group. No significant differences were found in age and sex distinction between the four groups (**Table [1](#T1){ref-type="table"}**).

Selection of candidate genes
----------------------------

Seven tumor-related genes, including *p16* (also known as *CDKN2A*), death-associated protein kinase (*DAPK*), *ZIC1*, *klotho*, *HOXD10*, *RUNX3* and Ras association domain family 1A (*RASSF1A*) were reported to have frequent promoter hypermethylation in GC [@B11]-[@B13], [@B16]-[@B19]. Firstly, we examined the methylation status of all 7 genes in the plasma of 10 GCs and 10 NCs. *p16* and *klotho* showed frequent hypermethylation of 40% (4/10) and 30% (3/10) in GC cases but were also aberrantly methylated in NCs, which was regarded as an exclusion criterion. None of the plasma samples tested showed methylation in *RASSF1A*. Therefore, *p16*, *klotho* and *RASSF1A* were excluded from the selection. *ZIC1* had the highest frequency of methylation (70%, 7/10) in the plasma of GCs with a lack of methylation in NCs. The methylation frequency of *DAPK*, *HOXD10*, *RUNX3* in GCs was 20% (2/10), 50% (5/10) and 40% (4/10), respectively, and none of them showed methylation in NCs. From the perspective of predictive power for GC, we selected *ZIC1*, *HOXD10* and *RUNX3* as the potential markers for detection of GC and conducted a validation study with larger sample sizes for further investigation.

Frequencies of aberrant ZIC1, HOXD10 and RUNX3 promoter methylation in plasma DNA
---------------------------------------------------------------------------------

Then, we examined the methylation status of *ZIC1*, *HOXD10* and *RUNX3* in expanded 251 cases. Methylation rate (MR) of *ZIC1*, *HOXD10* and *RUNX3* in each group was shown in **Figure [1](#F1){ref-type="fig"}.** MRs increased significantly in the progression of gastric carcinogenesis from NC to IM to IN to GC samples for all 3 genes (all *P*\<0.01 for IM, IN, EGC and AGC vs. NC). For *ZIC1* and *HOXD10*, higher MR was found in AGC compared to EGC samples, while the MR of *RUNX3*in plasma was higher in EGCs, rather than AGCs. For the NC group, none of the 3 genes were methylated in plasma DNA. In other words, the specificity of each individual biomarker was 100% for differentiating the GC and precancerous lesions from the NCs. Also, the frequencies of aberrant methylation in combined detection of multi-genes were analyzed (**Figure [2](#F2){ref-type="fig"},**all *P*\<0.01 for IM, IN, EGC and AGC vs. NC).

The mean number of genes methylated in IM, IN, EGC, and GC was 0.6, 1.2, 1.4 and 1.6, respectively. Concurrent methylation in 3 genes was found in none of IM, 7.1% of IN, 10% of EGC, and 13.7% of GC. Representative agarose gel electrophoresis results of the MSP for the three genes are shown in **Figure [3](#F3){ref-type="fig"}**.

Relationship between DNA methylation and clinicopathological characteristics
----------------------------------------------------------------------------

We analyzed the correlation of DNA methylation of each gene with clinical data (age, sex, H. pylori infection and serum CEA/ CA19-9 level) of all cases (**Table [2](#T2){ref-type="table"}**). There was no association between promoter hypermethylation of the 3 genes and age or gender. Methylation of *ZIC1*was associated with positive serum CA19-9 (*P*\<0.05). Methylation of *HOXD10* was more frequent in positive H. pylori infection cases (*P*\<0.05), in serum CA19-9 positive cases (*P*\<0.01) and in serum CEA positive cases (*P*\<0.01). However, no correlation was found between *RUNX3* hypermethylation and H. pylori status or serum CA19-9 and CEA levels.

We further investigated the association of the histopathologic findings with individual gene methylation in the plasma DNA from GCs (**Table [S2](#SM1){ref-type="supplementary-material"}**). The results revealed no marked associations between the methylation status of *ZIC1*, *RUNX3*promoter and the histopathologic features, including tumor location, size, grade, invasion depth, lymph node metastasis, distant metastasis and TNM staging. Interestingly, we discovered that the methylation status of *HOXD10* promoter was positively correlated with tumor invasion depth (*P*\<0.05); no correlations were found with other characteristics.

Effect of the combined detection of plasma ZIC1, HOXD10 and RUNX3 methylation for GC and GnI determination
----------------------------------------------------------------------------------------------------------

Multivariate regression analyses were performed to assess the predictive power of DNA methylation detection of plasma*ZIC1*,*HOXD10*and *RUNX3*for GC and GnI. The ORs of plasma *ZIC1*, *HOXD10* and *RUNX3* methylation for predicting the presence of GC were 4.285 (95%CI: 2.435-7.542; *P*\<0.01), 3.133 (95%CI: 1.700-5.775; *P*\<0.01) and 2.674(95%CI: 1.441-4.960; *P*\<0.01), respectively. However, the OR for predicting GnI was higher for *RUNX3*methylation (OR=12.794; 95%CI: 4.115-39.778; *P*\<0.01) than for *ZIC1* (OR=12.011; 95%CI: 5.050-28.564; *P*\<0.01) or *HOXD10*methylation (OR=9.174; 95%CI: 3.220-26.135; *P*\<0.01).

In order to investigate whether combined detection of the three genes was superior for early GC determination, we analyzed the sensitivity and specificity of the methylation detection with the use of singe or multi-gene panels; Youden index was calculated to estimate the accuracy of the plasma methylation assays (**Table [3](#T3){ref-type="table"}**). Though the specificity of combined detection was lower than that of single gene assays, the sensitivity for GC and GnI increased when 2 or 3 genes were detected together. Youden index of combined detection of 3 genes (parallel testing) was highest in both GC and GnI determination.

Discussions
===========

Aberrant promoter methylation of TSGs, which leads to silencing of genes, occurs early in the course of gastric carcinogenesis. Early detection yields the opportunity for improved survival rate and less invasive treatment. The notion of utilizing molecular approaches to discover epigenetic aberrations in circulating DNA have been considered as simple and non-invasive ways for GC diagnosis in large-scale populations. Recently, several genes such as *DAPK*, *E-cadherin*, *GSTP1*, *p16*and*XAF1* have been found methylated in the tumor and blood of GC patients [@B18], [@B20]. In our previous investigation of *ZIC1* promoter hypermethylation in the plasma, we found that the MR of *ZIC1* was 54.0% in the IN group and 60.6% in the GC group, indicating *ZIC1* a potential biomarker in early diagnosis of GC and precancerous lesions. However, the sensitivity of individual gene is limited. The combination of several biomarkers achieves greater sensitivity, and thus has been an emerging field in diagnosis.

Firstly, we selected three genes, including *ZIC1*, *HOXD10* and *RUNX3*, from seven frequently methylated TSGs (*p16*, *DAPK*, *ZIC1*, *klotho*, *HOXD10*, *RUNX3*, and *RASSF1A*) for further investigation. *ZIC1*, a vital transcription factor with zinc finger domains, is known to be a tumor suppressor in gastrointestinal cancers and modulate GC cell-cycle distributions and cell migration [@B21]. *HOXD10*, one of the homeobox (Hox) superfamily genes, plays critical roles in the differentiation of embryonic cells and progression of GC, and suppresses GC cell invasion by targeting*IGFBP3* [@B22]. *RUNX3*, a member of the human runt-related transcription factors, is an important target of transforming growth factor-β (*TGF-β*) superfamily signaling and play crucial roles not only in normal development, but also in carcinogenesis, especially stomach cancers [@B23], [@B24]. We and others have previously identified *ZIC1*, *HOXD10* and *RUNX3* as novel TSGs silenced through promoter hypermethylation in GC tissues, with the methylation frequencies of 94.6% (35/37), 83.5% (81/97) and 96% (43/45), respectively [@B12], [@B13], [@B16]. The combined application of *ZIC1*, *HOXD10* and *RUNX3* in blood DNA for GC and precancerous lesions detection is largely known.

In the present study, we found the MRs of *ZIC1*, *HOXD10* and *RUNX3* were 69.5%, 48.1% and 42.7% respectively in plasma from GCs. The fact that the MRs in plasma samples were lower than those in tissue samples may be illustrated by the explanation that tumor DNA gets into systemic circulation and then the methylation status of plasma DNA was detectable [@B25]. However, the exact mechanism about the origin of cfDNA in circulation remains unclear for the moment. Meanwhile, the absence of methylation occurred in all 3 selected genes from plasma DNA in NC cases, which is similar to the findings of other previous studies conducted in tissue samples of NCs [@B12]-[@B14]. Moreover, the MRs of all 3 genes increased with the histological progression from NCs, to IM, IN and GC, revealing that aberrant promoter methylation were gradually accumulated in GC development and detectable in the early stages of disease. We then analyzed the association of plasma DNA methylation with clinicopathological features. *ZIC1* and *HoxD10* methylation status in plasma was related to serum CA19-9/ CEA levels, which suggested that combination of promoter methylation of *ZIC1* or *HOXD10* with conventional serological tumor markers might be of great significance for further study. We found no marked associations between promoter methylation of *ZIC1*, *RUNX3* and the histopathologic features of gastric tumor. Surprisingly, the presence of methylated *HOXD10* in plasma was found to be associated with deeper tumor invasion, which is consistent to previous findings that ectopic expression of *HOXD10* impaired GC cell invasion and *HOXD10* promoter hypermethylation detected in GC tissues was associated with the TNM staging and indicated poor prognosis [@B12]. Also, *HOXD10* may be a marker in advanced stages, showing high levels of methylation in AGC but much lower levels in EGC.

Combined measurement of *ZIC1*, *HOXD10*and *RUNX3*methylation in plasma showed improved sensitivity and accuracy for early screening GC and precancerous lesions. Patients with IN lesions are more inclined to develop GC and advanced IN was considered as a warning sign. However, a very small proportion of biomarkers were validated for IN determination. Our results showed that *ZIC1*, *HOXD10* and *RUNX3* individually exhibited high risk associated with GC or GnI, and when detected together the sensitivity was improved to about 90% for GC and GnI, with the highest testing accuracy. It indicated that the combination of plasma *ZIC1*, *HOXD10* and *RUNX3* hypermethylation served as the most effective predictor of IN and GC. Since it takes a long time for the progression from precancerous lesions to GC, there may be a window of opportunity for discovering and curing advanced IN or EGC. With the help of combined methylation assays, it would be promising for early intervention in the stage of precancerous lesions and monitoring of gastric carcinogenesis. Further studies with other tools for mapping methylation aberrations are still required to estimate *ZIC1*, *HOXD10*, and *RUNX3* as useful biomarkers for early detection of GC and precancerous lesions.

In conclusion, aberrant promoter methylation of TSGs in body fluids has been considered to be a decent solution for the diagnosis of various cancers. Our findings demonstrated that the promoter MRs of *ZIC1*, *HOXD10* and *RUNX3* in plasma DNA was increased with the progression from precancerous lesions to GC. Combined assays of detecting plasma *ZIC1*, *HOXD10* and *RUNX3* methylation may be of great assistance in early detection of GC and in risk evaluation of high-risk populations.
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![Frequency of detecting methylated DNA in the plasma of AGC, EGC, IN, IM patients and NCs. ZIC1, Zinc finger of the cerebellum 1; HOXD10, Homeobox D10; RUNX3, runt-related transcription factor 3; NC, normal control; IM, intestinal metaplasia; IN, intraepithelial neoplasia; EGC, early gastric cancer; AGC, advanced gastric cancer.](jcav08p1038g001){#F1}

![The methylation rates of multi-genes detection in plasma samples according to gastric neoplastic progression. ZIC1, Zinc finger of the cerebellum 1; HOXD10, Homeobox D10; RUNX3, runt-related transcription factor 3; NC, normal control; IM, intestinal metaplasia; IN, intraepithelial neoplasia; EGC, early gastric cancer; AGC, advanced gastric cancer; +, parallel testing of multi-genes.](jcav08p1038g002){#F2}

![Representative agarose gel electrophoresis results of the methylation-specific polymerase chain reaction assay for ZIC1, HOXD10 and RUNX3 in plasma DNA (A, ZIC1; B, HOXD10; C, RUNX3). ZIC1, Zinc finger of the cerebellum 1; HOXD10, Homeobox D10; RUNX3, runt-related transcription factor 3; NC, normal control; IM, intestinal metaplasia; IN, intraepithelial neoplasia; GC, gastric cancer; M: Methylated-specific primers; U: Unmethylated-specific primers.](jcav08p1038g003){#F3}

###### 

The general characteristics of the study subjects.

                  GC (n=131)   IN (n=56)    IM (n=30)   NC (n=34)    *P*valu*e*
  -------- ------ ------------ ------------ ----------- ------------ ------------
  Age             61.1±10.77   59.6±10.07   57.8±9.55   56.5±10.55   0.086
  Gender   Male   88           37           18          22           0.902
  Female   43     19           12           12                       

GC, early gastric cancer; IN, intraepithelial neoplasia; IM, intestinal metaplasia; NC, normal control.

###### 

Correlation between methylation in plasma *ZIC1*, *HOXD10* and *RUNX3* and clinical parameters of all cases.

  Parameters     *ZIC1*     *HOXD10*      *RUNX3*                                                                               
  -------------- ---------- ------------- ------------- ------- ------------- ------------- ------- ------------- ------------- -------
  Age                       60.21±10.33   59.26±10.75   0.476   60.83±10.03   59.17±10.77   0.236   59.98±10.48   59.64±10.58   0.811
  Gender         Male       85            80            0.820   60            105           0.432   54            111           0.830
  Female         43         43            27            59      27            59                                                
  *H.pylori*     Yes        32            22            0.206   26            28            0.011   16            38            0.461
  No             86         88            51            123     61            113                                               
  Serum CA19-9   Positive   13            4             0.026   11            6             0.007   8             9             0.177
  Negative       104        111           70            145     67            148                                               
  Serum CEA      Positive   22            12            0.072   20            14            0.002   12            22            0.689
  Negative       95         103           61            137     63            135                                               

*ZIC1*, Zinc finger of the cerebellum 1; *HOXD10*, Homeobox D10; *RUNX3*, runt-related transcription factor 3; M = Methylated; U = Unmethylated.

###### 

Comparison of the diagnostic and predictive ability of plasma *ZIC1*, *HOXD10* and *RUNX3* methylation, when used alone or combined, in gastric cancer and intraepithelial neoplasia.

                            Sensitivity (95% CI)   Specificity (95%CI)   Youden index
  ------------------------- ---------------------- --------------------- --------------
  **GC**                                                                 
  *ZIC1*                    69.5% (60.7%-77.0%)    69.2% (60.0%-77.1%)   0.386
  *HOXD10*                  48.1% (39.3%-57.0%)    80.0% (71.5%-86.5%)   0.281
  *RUNX3*                   42.7% (34.2%-51.7%)    79.2% (70.6%-85.8%)   0.219
  *ZIC1*+*HOXD10*           82.4% (74.6%-88.3%)    58.3% (49.0%-67.2%)   0.408
  *ZIC1*+*RUNX3*            83.2% (75.5%-89.0%)    57.5% (48.1%-66.4%)   0.407
  *HOXD10*+*RUNX3*          72.5% (63.9%-79.8%)    65.0% (55.7%-73.3%)   0.375
  *ZIC1*+*HOXD10*+*RUNX3*   91.6% (85.1%-95.5%)    50.0% (40.8%-59.2%)   0.416
  **GnI**                                                                
  *ZIC1*                    64.2% (56.8%-70.9%)    87.5% (76.3%-94.1%)   0.517
  *HOXD10*                  43.9% (36.7%-51.3%)    92.2% (82.0%-97.1%)   0.360
  *RUNX3*                   41.2% (34.1%-48.6%)    93.8% (84.0%-98.0%)   0.349
  *ZIC1*+*HOXD10*           78.6% (71.9%-84.1%)    82.8% (70.9%-90.7%)   0.614
  *ZIC1*+*RUNX3*            80.2% (73.6%-85.5%)    84.4% (72.7%-91.9%)   0.646
  *HOXD10*+*RUNX3*          68.4% (61.2%-74.9%)    85.9% (74.5%-93.0%)   0.544
  *ZIC1*+*HOXD10*+*RUNX3*   89.8% (84.4%-93.6%)    79.7% (67.4%-88.3%)   0.695

*ZIC1*, Zinc finger of the cerebellum 1; *HOXD10*, Homeobox D10; *RUNX3*, runt-related transcription factor 3; GC, gastric cancer; GnI, gastric cancer and intraepithelial neoplasia.
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